ReviewAJNR. American journal of neuroradiology2016
Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.
Review in AJNR. American journal of neuroradiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
170 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging.JACC. Cardiovascular imaging · 2024Guideline
- A comparison of arterial spin labelling with catheter angiography in evaluating arteriovenous malformations: a systematic review.The British journal of radiology · 2020Pooled it
- Randomized study of the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.British journal of clinical pharmacology · 2020Trial
- Development and evaluation of a cervical cancer-specific restriction spectrum imaging (RSI) model.Magnetic resonance imaging · 2026Article
- The use of biparametric magnetic resonance imaging in active surveillance of prostate cancer.BJUI compass · 2026Article
- Effect of liver fibrosis on gadolinium retention from gadodiamide, gadobutrol, and gadoxetate disodium in rats.Japanese journal of radiology · 2026Article
- Relaxivity comparison of Gadoteric acid and Gadopiclenol using clinical and reference MRI sequences at 1.5 T.Magma (New York, N.Y.) · 2026Article
- Green MRI for neuroimaging: monitoring brain tumors using non-contrast sequences.Japanese journal of radiology · 2026Review
- BrainGAN Framework for Generating Synthetic Contrast-Enhanced Multisequence MRI in Brain Metastases.Journal of imaging informatics in medicine · 2026Article
- Deep learning-based generation of synthetic multiphasic MRI in hepatocellular carcinoma and cirrhosis.JHEP reports : innovation in hepatology · 2026Article
- Deep Learning-Based Synthetic Contrast-Enhanced Breast MRI for Monitoring Response to Neoadjuvant Therapy.Cancers · 2026Article
- Molecular imaging of immune and fibrosis targets to guide therapy for repair after myocardial infarction.Nature reviews. Cardiology · 2026Review
- Gadolinium-Based Contrast Agents and the Theater of Safety.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Feasibility of co-polarizing ¹³C-pyruvate and ¹³C-tert-butanol for simultaneous metabolic and perfusion imaging.Npj imaging · 2026Article
- A reversible rat model of hyposmia affects respiration-linked brain oscillations and behavior.iScience · 2026Article
- Magnetite nanodiscs as vortex-enhanced MRI contrast agents: a novel approach in medical imaging.Nanoscale advances · 2026Article
- Article
- Gadolinium Nanoparticles: Emerging Platforms Beyond Imaging for Drug Delivery and Theranostics.Pharmaceutics · 2026Review
- Redefining Pituitary Neuroendocrine Tumors in MEN1: Prevalence, Clinical Behavior, and Implications for Long-Term Surveillance.Current oncology (Toronto, Ont.) · 2026Article
- Deep learning-based non-contrast MRI model for nasopharyngeal carcinoma diagnosis: an end-to-end gadolinium-free solution.NPJ digital medicine · 2025Article
110 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byReply.2016
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In current practice, gadolinium-based contrast agents have been considered safe when used at clinically recommended doses in patients without severe renal insufficiency. The causal relationship between gadolinium-based contrast agents and nephrogenic systemic fibrosis in patients with renal insufficiency resulted in new policies regarding the administration of these agents. After an effective screening of patients with renal disease by performing either unenhanced or reduced-dose-enhanced studies in these patients and by using the most stable contrast agents, nephrogenic systemic fibrosis has been largely eliminated since 2009. Evidence of in vivo gadolinium deposition in bone tissue in patients with normal renal function is well-established, but recent literature showing that gadolinium might also deposit in the brain in patients with intact blood-brain barriers caught many individuals in the imaging community by surprise. The purpose of this review was to summarize the literature on gadolinium-based contrast agents, tying together information on agent stability and animal and human studies, and to emphasize that low-stability agents are the ones most often associated with brain deposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.